Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.66 |
| ▸ | CA9 | Q16790 | 6/20 | 0.66 |
| ▸ | CA1 | P00915 | 6/20 | 0.66 |
| ▸ | CA12 | O43570 | 5/20 | 0.66 |
| ▸ | CA4 | P22748 | 5/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.66 |
| ▸ | CA5A | P35218 | 4/20 | 0.66 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.66 |
| ▸ | CA3 | P07451 | 3/20 | 0.66 |
| ▸ | CA6 | P23280 | 3/20 | 0.66 |
| ▸ | CA7 | P43166 | 3/20 | 0.66 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30679676 | 1.00 | CA2 (0.66) | CA2CA9CA1CA12CA4 | |
| SCHEMBL18470093 | 0.93 | CA2 (0.66) | CA2CA9CA1CA12CA4 | |
| SCHEMBL20603564 | 0.93 | CA2 (0.68) | CA2CA9CA1CA12CA4 | |
| SCHEMBL16983590 | 0.89 | CA2 (0.61) | CA2CA9CA1CA12CA4 | |
| SCHEMBL3733081 | 0.84 | CA2 (0.71) | CA2CA9CA1CA12CA4 | |
| SCHEMBL3733073 | 0.84 | CA2 (0.71) | CA2CA9CA1CA12CA4 | |
| Fluorescein SCHEMBL20603559 | 0.82 | CA2 (0.49) | CA2CA9CA1CA12CA4 | |
| SCHEMBL3732449 | 0.79 | CA2 (1.00) | CA2CA9CA1CA12CA4 | |
| SCHEMBL3732451 | 0.79 | CA2 (1.00) | CA2CA9CA1CA12CA4 | |
| SCHEMBL3727802 | 0.79 | CA2 (0.70) | CA2CA9CA1CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381324-A1 | SMALL MOLECULE DRUG CONJUGATES | EIDGENOESSICHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381324-A1 | SMALL MOLECULE DRUG CONJUGATES | CA9, CA12, CA2 | CA2 3/4885CA9 1/4885CA1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.